Quantcast

Latest Adalimumab Stories

2011-05-10 08:00:00

ABBOTT PARK, Ill., May 10, 2011 /PRNewswire/ -- Abbott's (NYSE: ABT) HUMIRA® (adalimumab) met its primary endpoint of clinical remission in a Phase III study of adult patients with moderate to severe ulcerative colitis. Results were presented at the Digestive Disease Week (DDW) scientific conference in Chicago. Ulcerative colitis (UC) is a chronic autoimmune disease that causes inflammation and ulceration in the lining of the colon or large intestine. It is estimated...

2011-05-09 13:44:40

Health outcomes explored at DDW 2011 Adalimumab (ADA), a drug often prescribed for women with Crohn's disease, actively crosses the placenta during the final trimester of pregnancy and remains in a newborn's bloodstream for at least three months, researchers at the University of California San Francisco have found. The new study has implications for pregnant women and their obstetricians and pediatricians because ADA is known to decrease the immune system's ability to fight infection. Infants...

2011-05-09 07:00:00

CHICAGO, May 9, 2011 /PRNewswire/ -- New study findings showed that treatment with STELARA® (ustekinumab) induced and maintained clinical response in patients with moderate to severe Crohn's disease who had previously failed or were intolerant to at least one tumor necrosis factor (TNF) antagonist. Investigators presented findings from a Phase 2b study at Digestive Disease Week, which showed nearly 40 percent of patients receiving STELARA 6 mg/kg achieved clinical...

2011-04-20 06:24:00

ABBOTT PARK, Ill., April 20, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2011. Diluted earnings per share, excluding specified items, were $0.91, reflecting 12.3 percent growth. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.55, including costs associated with acquisition integration, cost-reduction initiatives and acquired in-process R&D. Worldwide sales increased 17.4...

2011-04-15 15:39:00

SILVER SPRING, Md., April 15, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Actemra (tocilizumab), given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in children ages 2 years and older. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) SJIA, or Still's disease, is a rare, potentially life-threatening disorder in children that causes severe inflammation throughout the...

2011-03-30 17:04:40

The American College of Rheumatology has developed new guidelines for starting and monitoring treatments for children with juvenile idiopathic arthritis. These are the first JIA guidelines endorsed by the ACR, with the goal of broad acceptance within the rheumatology community. Created as a guide for health care providers, the guidelines focus on the initiation and safety monitoring of multiple medications used in the treatment of JIA, including:     * Non-steroidal...

2011-03-08 15:35:49

Combination therapy for rheumatoid arthritis has consistent safety profile A recent trial of rituximab in combination with a tumor necrosis factor (TNF) inhibitor and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) found the safety profile to be consistent with other RA trials with TNF inhibitors. While the trial reported no new safety risks, clear evidence of an efficacy advantage in RA patients receiving the combination therapy was not observed in this study sample....

2296c9ac9c5a944551ae523e26ba9ce51
2011-03-04 18:55:00

Pfizer Inc. said on Friday that its rheumatoid arthritis drug met the main goals of a late-stage clinical trial. The drug is one of the most important in Pfizer's pipeline.  The company said the safety profile of the drug was consistent with that seen previously in the clinical program. The trial showed the drug reduced the signs and symptoms of rheumatoid arthritis by a statistically significant amount, compared with a placebo at six months. The trial tested the drug in patients with...

2011-03-01 08:00:00

SAN DIEGO, March 1, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today highlighted its financial results and product development progress for the year ended December 31, 2010. "Prometheus had another record year in 2010, our 14th consecutive year of sales growth," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "In addition, we made significant progress advancing a number of internal development programs,...

2011-02-16 12:48:38

Some biologic drugs may be safer than others according to a new systematic review by Cochrane researchers. Biologics are a broad class of drugs based on biological molecules. The drugs are used to reduce inflammation in diseases such as rheumatoid arthritis and inflammatory bowel disease. Although the effectiveness of biologics is now well established, it is thought that some may have rare but serious side effects related to their immune-suppressing activities. Links have been made to...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related